يعرض 1 - 10 نتائج من 56 نتيجة بحث عن '"Medicaments - Eficàcia"', وقت الاستعلام: 0.85s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Rivera-Díaz R Department of Dermatology, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain. Pozo T Department of Dermatology, Hospital Rio Hortega, Valladolid, Spain. Alfageme F Department of Dermatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid,Spain. Díaz Ley B Department of Dermatology, Hospital Universitario del Sureste, Arganda, Madrid, Spain. Osorio GF Department of Dermatology, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain. Chico R Department of Dermatology, Hospital Infanta Sofía, Alcobendas, Madrid, Spain. Romaní J Department of Dermatology, Hospital General de Granollers, Granollers, Spain, Hospital General de Granollers

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Actas Dermo-Sifiliográficas;114(9); https://doi.org/10.1016/j.ad.2023.06.013Test; Rivera-Díaz R, Pozo T, Alfageme F, Díaz Ley B, Osorio GF, Chico R, et al. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study. Actas Dermosifiliogr. 2023 Oct;114(9):755-762.; https://hdl.handle.net/11351/11181Test

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Fornaguera M, Rodrigo-Pendás JÁ, Tejada G, Guananga D, Vivet-Escalé M, Peñalver-Piñol A, Torrecilla-Martínez I Servei de Medicina Preventiva i Epidemiologia, Vall d′Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca d’Epidemiologia i Salut Pública, Vall d′Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d′Hebron Hospital Universitari, Barcelona, Spain. Parés-Badell O, Borras-Bermejo B, Armadans-Gil L, Martínez-Gómez X, Otero-Romero S Servei de Medicina Preventiva i Epidemiologia, Vall d′Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca d’Epidemiologia i Salut Pública, Vall d′Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d′Hebron Hospital Universitari, Barcelona, Spain. Unitat Docent, Vall d′Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Carbonés-Fargas Í Grup de Recerca d’Epidemiologia i Salut Pública, Vall d′Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d′Hebron Hospital Universitari, Barcelona, Spain. Andrés C, Antón A Unitat de Virus Respiratoris, Vall d′Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Microbiologia, Vall d′Hebron Hospital Universitari, Barcelona, Spain. CIBERINFEC, ISCIII-CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain. del Oso A Direcció de Sistemes de la Informació, Vall d′Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Vaccines;11(9); https://doi.org/10.3390/vaccines11091450Test; Fornaguera M, Parés-Badell O, Carbonés-Fargas Í, Andrés C, Rodrigo-Pendás JÁ, Borras-Bermejo B, et al. Influenza Vaccine Effectiveness against Hospitalization, Season 2021/22: A Test-Negative Design Study in Barcelona. Vaccines (Basel). 2023 Sep 2;11(9):1450.; https://hdl.handle.net/11351/10409Test

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Villar J Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK. Oxford Maternal and Perinatal Health Institute, Green Templeton College, University of Oxford, Oxford, UK. Soto Conti CP Division Neonatología, Hospital Materno Infantil Ramón Sarda, Buenos Aires, Argentina. Gunier RB Center for Environmental Research and Community Health (CERCH), School of Public Health, University of California, Berkeley, CA, USA. Ariff S Department of Paediatrics and Child Health, The Aga Khan University Hospital, Karachi, Pakistan. Craik R Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, UK. Cavoretto PI Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute, Obstetrics and Gynaecology Department, Milan, Italy. Maiz N Unitat de Medicina Fetal, Unitat Docent d’Obstetrícia i Ginecologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Lancet;401(10375); https://doi.org/10.1016/S0140-6736Test(22)02467-9; Villar J, Soto Conti CP, Gunier RB, Ariff S, Craik R, Cavoretto PI, et al. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. Lancet. 2023 Feb 11;401(10375):447–57.; https://hdl.handle.net/11351/9167Test

  4. 4
    دورية أكاديمية

    المساهمون: Ríos-Tamayo R Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. Soler JA Department of Hematology, HospitalUniversitari Parc Taulí de Sabadell, Catalonia, Spain. García-Sánchez R Department of Hematology, Hospital Virgen de la Victoria, Málaga, Spain. Pérez Persona E Department of Hematology, Hospital Universitario de Navarra, Pamplona, Spain. Arnao M Department of Hematology, Hospital Universitari i Politècnic La Fe, Valencia, Spain. García-Guiñón A Department of Hematology, Hospital Universitari Arnau de Vilanova, Lleida, Spain. Domingo A Department of Hematology, Hospital General de Granollers, Granollers, Spain. González-Pardo M Medical Department, Janssen-Cilag España, Spain. de la Rubia J Hospital Universitari i Politècnic La Fe, Valencia, Spain. Hematology Department, Universidad Católica“San Vicente Mártir”, Valencia, Spain. CIBERONC CB16/12/00284,Valencia, Spain. Mateos MV Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Hospital Universitario de Salamanca, Salamanca, Spain, Hospital General de Granollers

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Hematology;28(1); https://doi.org/10.1080/16078454.2023.2178997Test; Ríos-Tamayo R, Soler JA, García-Sánchez R, Pérez Persona E, Arnao M, García-Guiñón A, et al. A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study. Hematology. 2023 Dec;28(1):2178997.; https://hdl.handle.net/11351/9425Test

  5. 5
    تقرير

    المساهمون: Blanco L, Vives R Divisió d'ús Racional del Medicament, Gerència del Medicament, Servei Català de la Salut (CatSalut), Generalitat de Catalunya, Barcelona, Spain. de Pando T, Molina A Divisió de Prestacions Farmacèutiques, Gerència del Medicament, Servei Català de la Salut (CatSalut), Generalitat de Catalunya, Barcelona, Spain, Departament de Salut

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Lídia B, de Pando T, Molina A, Vives R. Argumentari de l’índex de qualitat de la prescripció farmacèutica per als centres de salut mental d’adults (IQF-CSMA). Versió 2023. Barcelona: Servei Català de la Salut; 2023.; https://hdl.handle.net/11351/9945Test

  6. 6
    تقرير
  7. 7
    تقرير
  8. 8
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Manzano-Muñoz A Nanobioengineering Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Yeste J, López A Biosensors for Bioengineering Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Ortega MA Biosensors for Bioengineering Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Vitala Technologies, Barcelona, Spain. Martín F Nanobioengineering Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. Networking Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain. Rosell J Sarcoma Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Castro S Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Serrano C Sarcoma Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: NPJ Precision Oncology;6; https://doi.org/10.1038/s41698-022-00333-0Test; info:eu-repo/grantAgreement/EC/H2020/863037; Manzano-Muñoz A, Yeste J, Ortega MA, Martín F, López A, Rosell J, et al. Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy. NPJ Precis Oncol. 2022 Dec 1;6:90.; https://hdl.handle.net/11351/9553Test; 000912882600001

  9. 9
    دورية أكاديمية

    المساهمون: Teira R Service of Internal Medicine, Hospital de Sierrallana, Torrelavega, Spain. Diaz-Cuervo H Gilead Sciences, MAOR, London, UK. Aragão F Maple Health Group, New York City, NY, USA. NOVA National School of Public Health, Public Health Research Centre, Unversidade NOVA de Lisboa, Lisboa, Portugal. Castaño M Hospital Regional Universitario de Málaga, Málaga, Spain. Romero A Hospital Universitario de Puerto Real, Puerto Real, Spain. Roca B Hospital General de Castellón, Castellón, Spain. Deig E Hospital General de Granollers, Granollers, Spain. Currán A Vall d’Hebron Hospital Universitari, Barcelona, Spain, Hospital General de Granollers

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Infectious Diseases and Therapy;11; https://doi.org/10.1007/s40121-022-00630-yTest; Teira R, Diaz-Cuervo H, Aragão F, Castaño M, Romero A, Roca B, et al. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort. Infect Dis Ther. 2022 Apr 11;11:1177-92.; https://hdl.handle.net/11351/7940Test

  10. 10
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Hollebecque A Gustave Roussy, Département d’innovation thérapeutique et essais précoces, Villejuif, France. Salvagni S S. Orsola Polyclinic, Malpighi University Hospital, Bologna, Italy. Plummer R Clinical and Translational Research Institute Northern, Newcastle University, Newcastle, UK. Niccoli P Department of Medical Oncology, ENETS Center of Excellence, IPC NET Center, Institut Paoli-Calmettes, Marseille, France. Capdevila J Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. IOB-Teknon, Barcelona, Spain. Curigliano G European Institute of Oncology, IRCCS, University of Milan, Milan, Italy, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Cancer;128(17); https://doi.org/10.1002/cncr.34366Test; Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, et al. Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer. 2022 Sep 1;128(17):3185–95.; https://hdl.handle.net/11351/8150Test; 000814787400001